Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3488361 | 0.89 | SMN1; SMN2 (0.55) | KMT2ACYP3A4CYP2C19POLBALDH1A1 | |
| SCHEMBL16485924 | 0.88 | KMT2A (0.53) | KMT2ACYP3A4CYP2C19POLBALDH1A1 | |
| SCHEMBL1269684 | 0.87 | CYP3A4 (0.67) | KMT2ACYP3A4CYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL20488351 | 0.87 | KMT2A (0.55) | KMT2AALDH1A1 | |
| SCHEMBL3488086 | 0.83 | MMP1 (0.49) | KMT2ACYP3A4CYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL14750015 | 0.82 | BTK (0.66) | KMT2APOLBALDH1A1 | |
| SCHEMBL17062184 | 0.82 | GAA (0.50) | KMT2ACYP3A4CYP2C19POLBALDH1A1 | |
| SCHEMBL16759341 | 0.82 | GAA (0.50) | KMT2ACYP3A4CYP2C19POLBALDH1A1 | |
| SCHEMBL16485861 | 0.79 | GAA (0.50) | KMT2ACYP3A4CYP2C19ALDH1A1L3MBTL1 | |
| SCHEMBL28050302 | 0.79 | ALDH1A1 (0.49) | KMT2ACYP3A4CYP2C19POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111251-A1 | COMPOUNDS THAT INHIBIT POLO-LIKE KINASE 4 | EXELIXIS, INC. (US) | 2025-05-30 | — | — | WO | disclosed |
| US-9670211-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670211-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9670211-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3033341-B1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2017-05-03 | — | — | EP | disclosed |
| EP-3033341-B1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2017-05-03 | — | — | EP | disclosed |
| US-20160229853-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229853-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-08-11 | — | — | US | disclosed |
| US-20160229853-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-08-11 | — | — | US | disclosed |
| EP-3033341-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F.HOFFMANN-LA ROCHE AG (CH) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015022263-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-19 | — | — | WO | disclosed |
| WO-2015022263-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-19 | — | — | WO | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| US-20100056497-A1 | AMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD (JP) | 2010-03-04 | — | — | US | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
| EP-2119702-A1 | AMIDE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229853-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, TET1, IDO1 | KMT2A 363/4885CYP3A4 235/4885CYP2C19 306/4885 |
| US-20100056497-A1 | AMIDE DERIVATIVE | REN, AGTR1, AGTR2 | KMT2A 921/4885CYP3A4 537/4885CYP2C19 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.